NEW YORK – Appropriately enough on Valentine's Day, there was news of a blossoming hook-up coming out of the BIO CEO & Investor Conference. The marriage of biopharma drugs and medical technology to develop the companion diagnostics market could be primed to deliver smart therapeutics and produce a family of hybrid products that have the capacity to prematurely discover disease, abort its onset or nurse its symptoms.